Shares of Health Care sector company Gilead Sciences moved -2.6% today, and are now trading at a price of $66.59. The Large-Cap stock's daily volume was 3,973,407 compared to its average volume of 7,683,675. The S&P 500 index returned a 0.0% performance.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company is based in Foster City and has 18,000 full time employees. Its market capitalization is $82,961,145,856. Gilead Sciences currently offers its equity investors a dividend that yields 4.4% per year.
25 analysts are following Gilead Sciences and have set target prices ranging from $62.4 to $110.83 per share. On average, they have given the company a rating of buy. At today's prices, GILD is trading -12.27% away from its average analyst target price of $75.9 per share.
Over the last year, GILD shares have gone down by -12.7%, which represents a difference of -38.2% when compared to the S&P 500. The stock's 52 week high is $87.87 per share and its 52 week low is $62.07. Although Gilead Sciences's average free cash flow over the last 5 years has been $8.31 Billion, they have been decreasing at an average rate of -1.2%. For this reason, investors may continue to shun the stock.
Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
---|---|---|---|---|
2023 | 8,006,000 | 585,000 | 7,421,000 | -11.06 |
2022 | 9,072,000 | 728,000 | 8,344,000 | -22.78 |
2021 | 11,384,000 | 579,000 | 10,805,000 | 43.72 |
2020 | 8,168,000 | 650,000 | 7,518,000 | -9.63 |
2019 | 9,144,000 | 825,000 | 8,319,000 | 11.28 |
2018 | 8,400,000 | 924,000 | 7,476,000 |